Advertisement
Product › Details
Zontivity®
Next higher product group | vorapaxar | |
Status | 2014-05-08 registration start | |
Organisation | Merck & Co. Inc. (NYSE: MRK) | |
Group | Merck (US) (MSD) (Group) | |
Organisation 2 | Schering-Plough Corporation (NYSE: SGP) | |
Today | Merck & Co. Inc. (NYSE: MRK) | |
Group | Merck (US) (MSD) (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for anticoagulant_o
- [1] AdvanceCor GmbH. (6/2/20). "Press Release: AdvanceCor GmbH Closes a further Financing Round with a Consortium of Investors". München/Martinried....
- [2] Cerenis Therapeutics S.A.. (1/24/19). "Press Release: 2018 Annual Results and Clinical Update". Toulouse & Lakeland, US....
- [3] Boehringer Ingelheim. (11/15/17). "Press Release: Key Sub-analyses of RE-DUAL PCI Showed Large Reductions in the Incidence of Bleeding Complications if Pradaxa (dabigatran etexilate) Dual Therapy Was Used Instead of Warfarin Triple Therapy". Ingelheim....
- [4] Cerenis Therapeutics S.A.. (2/17/16). "Press Release: 2016 Annual Results. Solid Cash Position of €24.7 million and Finalization of CARAT Phase 2 Clinical Study". Toulouse & Ann Arbor, MI....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top